Non Small Cell Lung Cancer research hub
50 indexed studies · 31 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
This clinical trial is testing a new drug called petosemtamab combined with an established immunotherapy called pembrolizumab (Keytruda). It aims to find out if this combination is safe and effective at shrinking tumours in adults diagnosed with non-small cell lung cancer.
Spain · Belgium · Netherlands - authorisedTherapeutic exploratory (Phase II)
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
This clinical study tests a new immunotherapy drug called rilvegostomig for adults with stage 3 non-small cell lung cancer that cannot be removed by surgery. Researchers want to see if adding it to standard chemotherapy and radiotherapy is safe and helps control the cancer better.
Spain · Germany - authorisedPhase II and Phase III (Integrated)
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
This study looks at the best order to give treatments to people with advanced non-small cell lung cancer linked to specific gene changes. Researchers want to see which treatment sequence keeps the cancer under control for longer and helps people maintain a good quality of life.
Italy - authorisedPhase I and Phase II (Integrated)- Other
PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER
This study looks at using specialised PET scans for people with non-small cell lung cancer. Researchers want to see if these scans can show early on whether treatment given before surgery is working. The aim is to help doctors tailor lung cancer treatments more quickly and effectively in the future.
Netherlands · Germany - authorisedTherapeutic exploratory (Phase II)
EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.
This study tests the best way to treat non-small cell lung cancer that has spread to the brain without causing symptoms. It compares giving targeted brain radiotherapy before drug treatment against starting drug treatment (chemotherapy plus a new medicine called ivonescimab) straight away to see which controls tumours better.
Netherlands - recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy
This study looks at a new treatment for people with a certain type of lung cancer that has been removed by surgery. It compares two medicines, Tiragolumab and Atezolizumab, against Atezolizumab alone, to see if the new combination can help prevent the cancer from coming back.
Germany · Austria · Belgium - recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)
This study is looking at new treatments for advanced lung cancer. It combines standard chemotherapy with a drug called pembrolizumab, sometimes adding another drug called canakinumab, to see if this mix is more effective and safe for patients.
Spain · Germany - recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer
This study is looking at a new treatment for advanced lung cancer. It combines a special cell therapy (ATL001) with existing treatments like KEYTRUDA. The main goal is to check how safe these treatments are and if they help shrink tumours. It's for adults with non-small cell lung cancer.
Spain · Germany · France - recruitingHuman Pharmacology (Phase I)- Other
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at a new combination of medicines for people with advanced lung cancer. It combines an experimental drug, Dato-DXd, with pembrolizumab, a common cancer medicine, sometimes also with chemotherapy. It's an early-stage study to see if it's safe and how it works.
Spain · Italy - recruitingTherapeutic exploratory (Phase II)
C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer
This study is looking at two drugs, encorafenib and binimetinib, for a type of lung cancer called non-small cell lung cancer. It's for patients whose cancer has a specific change called a BRAFV600 mutation. Researchers want to see how well these drugs shrink the cancer.
Netherlands · Spain · Italy - recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
France · Poland · Ireland - recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
Czechia · Poland · Greece - recruitingTherapeutic exploratory (Phase II)
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)
This study is for adults with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to previous immune-boosting treatments. It's testing new combinations of medicines to see if they can help control the cancer, looking at how many people's cancer stops growing or shrinks after 12 weeks.
France - recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
This study is testing a new cancer 'vaccine' called PDC*lung01 for non-small-cell lung cancer. It checks if it's safe, how well people can tolerate it, and if it helps fight the cancer, sometimes with another drug called anti-PD-1.
France · Germany · Netherlands - recruitingTherapeutic confirmatory (Phase III)
A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients with PD L1 expression ≥50% on tumor cells : PERSEE TRIAL
This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It compares two different treatment plans using a medicine called pembrolizumab to see which works best for people with a specific marker on their cancer cells.
France - recruitingTherapeutic exploratory (Phase II)
I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
This study looks at a new drug, LY2875358, combined with an existing lung cancer treatment, erlotinib, for people with a specific type of advanced non-small cell lung cancer. It compares this combination to using erlotinib alone to see if it helps patients live longer without their cancer growing.
Spain · Germany - recruitingTherapeutic confirmatory (Phase III)
IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
This study looks at a new way to treat advanced lung cancer. It compares continuing a combination of two immunotherapy drugs (Nivolumab and Ipilimumab) after initial treatment with simply watching to see what happens. The goal is to find out which approach works better at keeping the cancer from growing.
France - authorisedTherapeutic exploratory (Phase II)
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
This study is looking at a new drug called Cabozantinib for a type of lung cancer called non-small cell lung cancer (NSCLC). It's for people whose cancer has specific genetic changes related to a protein called MET. Researchers want to see how well the drug shrinks tumours.
Italy - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study looks at a new drug, AZD0022, for people with certain types of lung, bowel, and pancreatic cancer. Doctors want to see if it's safe, how the body handles it, and if it can help shrink tumours, both on its own and with other cancer drugs.
Belgium · Poland · Italy - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors
This study is testing a new medicine, PF-08046031, for adults with advanced melanoma (a type of skin cancer) and other solid cancers like lung, head and neck, and oesophageal cancer. This is an early-stage study to see if the medicine is safe and how it works in the body.
Germany · Sweden · France - recruitingTherapeutic exploratory (Phase II)
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q]
This study is for people with a type of lung cancer that can be removed with surgery. It looks at new treatments given before and after surgery to see if they can help shrink the cancer and stop it from coming back.
Germany - recruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
United States · Argentina · Australia - recruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
United States · Argentina · Belgium - available
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This program offers people with advanced ALK-positive lung cancer or other ALK-positive tumours an opportunity to receive an investigational medicine called neladalkib (NVL-655). It is for those who can't join a regular trial and have run out of other good treatment options.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
United States · Argentina · Australia - recruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
United States · Argentina · Australia - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
United States · Australia · Belgium - active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
This study looks at new treatments (Durvalumab and Domvanalimab) for advanced lung cancer (Stage III NSCLC) after standard radiation and chemotherapy. It aims to see if combining these medicines helps patients whose cancer hasn't worsened after initial treatment.
United States · Belgium · Brazil - active not recruitingPHASE1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
This study tests a new medicine called zongertinib for advanced cancers with changes in the HER2 gene. It aims to find the right dose and see if it can shrink tumours, especially in non-small cell lung cancer.
United States · Australia · Austria - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
United States · Argentina · Brazil - recruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This study looks at a new drug, selpercatinib, for advanced cancers, including certain lung, thyroid, and other solid tumours that have a specific genetic change called a RET alteration. Researchers want to check its safety, how it works in the body, and if it helps shrink tumours.
United States · Australia · Canada - active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
This study looks at combining a drug called osimertinib with chemotherapy for a type of lung cancer. It wants to see if this combination works better than osimertinib alone for patients with a specific genetic change in their cancer, hoping to delay the cancer getting worse.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
This study is for people with a certain type of lung cancer (NSCLC) that has a specific gene change (KRAS G12C). It's testing a new drug, calderasib, alongside a common immunotherapy, durvalumab, to see if this combination helps more after standard chemotherapy and radiation.
United States · Argentina · Australia - active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
United States · Argentina · Austria - recruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
United States · Argentina · Australia - available
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
This program offers a new medicine called zidesamtinib to adult patients in the UK with advanced ROS1-positive lung cancer or other ROS1-positive cancers. It's for those who have tried other treatments, can't join a regular trial, and have few other options available.
Australia · Belgium · Canada - active not recruitingPHASE3
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study compares a new drug, DS-1062a, with a standard chemotherapy, docetaxel, for advanced lung cancer. It's for people whose cancer has grown after previous treatments. We want to see if DS-1062a is safer and works better.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
United States · Austria · Brazil - recruitingPHASE3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This study is testing a new drug combination for a specific type of lung cancer that has been removed by surgery. It compares two treatments: a new drug (Calderasib) with an existing one (MK-3475A), against the existing drug plus a dummy treatment, to see if it helps stop the cancer from coming back.
Argentina · Australia · Brazil - active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
This study looks at a new drug, selpercatinib, for people with a type of lung cancer that has spread. It compares this new drug to standard treatments to see if it's safe and works well for their specific cancer type.
Argentina · Australia · Belgium - recruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
United States · Argentina · Belgium - recruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
United States · Argentina · Australia - recruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
United States · Argentina · Austria - recruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
United States · Argentina · Australia - recruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
United States · Argentina · Australia - active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
United States · Australia · Belgium - active not recruitingPHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new combinations of medicines for advanced lung cancer that has spread. It combines a drug called sacituzumab govitecan (SG) with pembrolizumab, and sometimes with chemotherapy agents like carboplatin or cisplatin, to see how well they work together.
United States · Australia · Canada - recruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
United States · Argentina · Australia